HK1102367A1 - Methods for treatment of disease-induced peripheral neuropathy and related conditions - Google Patents

Methods for treatment of disease-induced peripheral neuropathy and related conditions

Info

Publication number
HK1102367A1
HK1102367A1 HK07109356.2A HK07109356A HK1102367A1 HK 1102367 A1 HK1102367 A1 HK 1102367A1 HK 07109356 A HK07109356 A HK 07109356A HK 1102367 A1 HK1102367 A1 HK 1102367A1
Authority
HK
Hong Kong
Prior art keywords
treatment
disease
methods
peripheral neuropathy
related conditions
Prior art date
Application number
HK07109356.2A
Other languages
English (en)
Inventor
Jack Diamond
Alvin J Glasky
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of HK1102367A1 publication Critical patent/HK1102367A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Treatment Devices (AREA)
HK07109356.2A 2000-07-07 2007-08-28 Methods for treatment of disease-induced peripheral neuropathy and related conditions HK1102367A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21684400P 2000-07-07 2000-07-07

Publications (1)

Publication Number Publication Date
HK1102367A1 true HK1102367A1 (en) 2007-11-16

Family

ID=22808722

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109356.2A HK1102367A1 (en) 2000-07-07 2007-08-28 Methods for treatment of disease-induced peripheral neuropathy and related conditions

Country Status (9)

Country Link
US (2) US6630478B2 (fr)
EP (3) EP1790344B1 (fr)
AT (2) ATE499103T1 (fr)
AU (2) AU2001273212A1 (fr)
DE (2) DE60143850D1 (fr)
DK (2) DK1790344T3 (fr)
ES (2) ES2385931T3 (fr)
HK (1) HK1102367A1 (fr)
WO (2) WO2002004452A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195302A1 (fr) * 1994-07-25 1996-02-08 Alvin J. Glasky Modificateurs du guanylyle dependants du monoxyde de carbone
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
WO2003105845A1 (fr) * 2002-06-14 2003-12-24 Takeda Chemical Industries, Ltd. Promedicaments de derives d'imidazole servant d'inhibiteurs de pompe a protons dans le traitement de l'ulcere gastro-duodenal
WO2005030148A2 (fr) * 2003-09-25 2005-04-07 Cenomed, Inc. Derives de tetrahydroindolone destines au traitement d'etats neurologiques
WO2005048926A2 (fr) 2003-11-13 2005-06-02 The General Hospital Corporation Methodes pour traiter la douleur
US8012964B2 (en) * 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
AU2006244074B2 (en) * 2005-05-09 2012-12-13 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
US8916550B2 (en) 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
JP2009545619A (ja) * 2006-08-01 2009-12-24 スペクトラム ファーマシューティカルズ インコーポレイテッド 化学療法誘発神経障害の治療に寄与するための方法および医薬製剤
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
JP5329444B2 (ja) * 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
PT2132209E (pt) * 2007-03-19 2014-04-15 Astrazeneca Ab Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
EP2138497A4 (fr) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co Nouveau composé d'adénine
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
PL2155743T3 (pl) * 2007-05-08 2013-01-31 Astrazeneca Ab Imidazochinoliny o właściwościach immunomodulacyjnych
WO2009031154A2 (fr) * 2007-09-07 2009-03-12 Beta O2 Technologies Ltd. Couche d'air pour soutenir des cellules
EA018414B1 (ru) * 2007-10-11 2013-07-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
EP2219648A4 (fr) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc Traitement des troubles du stress post-traumatique avec des composés de tétrahydroindolone et d'arylpipérazine
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JPWO2009091031A1 (ja) * 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
KR20100125245A (ko) 2008-01-17 2010-11-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 아데닌 화합물의 제조 방법
US9483755B2 (en) * 2008-03-04 2016-11-01 Apple Inc. Portable multifunction device, method, and graphical user interface for an email client
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
MX340198B (es) 2008-08-29 2016-06-30 A Schulman Inc * Composiciones polimericas con sabor optimizado.
EP2507237A1 (fr) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr)
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2651937B8 (fr) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Dérivé imidazo[4,5-c]quinolin-1-yle utile en thérapie
WO2012080730A1 (fr) 2010-12-17 2012-06-21 Astrazeneca Ab Dérivés de purine
US20160166618A1 (en) * 2012-10-19 2016-06-16 Anthrogenesis Corproation Treatment of pain using amnion derived adherent cells
WO2015058141A1 (fr) * 2013-10-18 2015-04-23 Virginia Tech Intellectual Properties, Inc. Monomères et copolymères contenant des nucléobases
US9898162B2 (en) 2014-05-30 2018-02-20 Apple Inc. Swiping functions for messaging applications
WO2016036509A1 (fr) 2014-09-02 2016-03-10 Apple Inc. Interface utilisateur de courrier électronique
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
WO2023055531A1 (fr) * 2021-09-28 2023-04-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Méthodes de traitement de la neuropathie périphérique

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300380A (en) 1963-12-26 1967-01-24 Upjohn Co Diminishing toxicity of antiviral nu6-(hydroxyalkyl) adenines with 4-hydroxypyrazolo(3, 4-d) pyrimidine
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438968A (en) 1966-06-23 1969-04-15 Int Chem & Nuclear Corp Substituted ammonium basic addition salts of ribonucleic acid
BE759011A (fr) 1969-11-17 1971-05-17 Wellcome Found Aminopurines
DE2554453A1 (de) 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
GB1530912A (en) 1975-02-13 1978-11-01 Wellcome Found Compositions containing 9-(2-hydroxy-3-alkyl)-adenines
US4138562A (en) 1977-02-09 1979-02-06 The Regents Of The University Of Minnesota Adenosine deaminase resistant antiviral purine nucleosides and method of preparation
US4221910A (en) 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4340726A (en) 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4347360A (en) 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4451478A (en) 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US5495010A (en) 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
ATE140729T1 (de) 1988-04-19 1996-08-15 Pasteur Institut Verfahren zur gewinnung von schutzantigenen gegen bordetella-infektionen und toxische prozesse
US5256677A (en) 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5091432A (en) * 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5646155A (en) * 1994-05-12 1997-07-08 University Of Massachusetts Medical Center Drugs to prevent recurrent herpes virus infections
CA2195302A1 (fr) * 1994-07-25 1996-02-08 Alvin J. Glasky Modificateurs du guanylyle dependants du monoxyde de carbone
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5795756A (en) 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
AU709323B2 (en) 1996-03-15 1999-08-26 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
WO1999057120A1 (fr) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Nouvelle hypoxanthine 9-substituee apparentee a la serotonine
WO1999056550A1 (fr) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Methode de traitement de la migraine chez des mammiferes
WO1999057119A1 (fr) 1998-05-04 1999-11-11 Neotherapeutics, Inc. Nouvelle hypoxanthine 9-substituee de type dopamine et methodes d'utilisation
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
US6297226B1 (en) * 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives

Also Published As

Publication number Publication date
DK1334103T3 (da) 2011-04-04
US6630478B2 (en) 2003-10-07
ATE499103T1 (de) 2011-03-15
DK1790344T3 (da) 2011-05-02
EP1790344B1 (fr) 2011-02-23
ES2420354T3 (es) 2013-08-23
WO2002004452A3 (fr) 2003-01-03
WO2002004448A3 (fr) 2003-01-23
EP1790344A2 (fr) 2007-05-30
EP1790344A3 (fr) 2007-06-27
WO2002004448A2 (fr) 2002-01-17
AU2001273212A1 (en) 2002-01-21
EP1334103B1 (fr) 2011-01-12
ATE495177T1 (de) 2011-01-15
US20020055506A1 (en) 2002-05-09
US6630490B2 (en) 2003-10-07
US20020061899A1 (en) 2002-05-23
EP1334104A2 (fr) 2003-08-13
EP1334103A2 (fr) 2003-08-13
WO2002004452A2 (fr) 2002-01-17
DE60144123D1 (de) 2011-04-07
DE60143850D1 (de) 2011-02-24
AU2001271908A1 (en) 2002-01-21
ES2385931T3 (es) 2012-08-03

Similar Documents

Publication Publication Date Title
HK1102367A1 (en) Methods for treatment of disease-induced peripheral neuropathy and related conditions
BG110708A (en) MEANS THAT ENOUGH THE GROWTH HORMONE SECRET
IL161908A0 (en) Quinazoline derivatives for the treatment of abnormal cell growth
BG108181A (en) Novel spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
GEP20094700B (en) Biphenyl derivatives, fungicidal composition containing it and method of controlling phytopathogenic microorganisms
GB0114185D0 (en) Compounds
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
AU2634597A (en) Compounds with growth hormone releasing properties
EP1408751A4 (fr) Procedes inhibant les reponses a l'ethylene par des plantes
AU2002320510A1 (en) Method of improving plant growth
AU2003213661A8 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
HUP0500117A3 (en) Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
MXPA03012039A (es) Derivados de benzo [g]quinolina para tratar glaucoma y miopia.
UA85994C2 (en) N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
RS20050359A (en) Fungicidal mixtures
RS20050959A (en) Fungicidal mixtures for controlling rice pathogens
IL153674A0 (en) 13-substituted methacycline compounds
AU2002338794A1 (en) Use of mannosamine derivatives for the stimulation of neurite growth
RS20050958A (en) Fungicidal mixtures
GB0122102D0 (en) Chamber for growing plants
EP1296703A4 (fr) Tetracycline non antibacterienne en tant qu'agent antifongique
WO2005036960A3 (fr) Melanges fongicides pour lutter contre des agents pathogenes du riz
AU2001244537A1 (en) Use of natural compounds having antiangiogenic activity

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150706